Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)


This observational study of a national cohort of 600 Swedish PSC patients include yearly MR/MRCP, biobanking of serum, plasma and blood, followup clinical data (interventions, symptoms, labs, colonoscopy). The aim is to collect a well characterized cohort of PSC patients and provide future possibilities to evaluate biomarkers for prognosis and early cancer detection.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 31, 2016


  • Diagnostic Test: MR/MRCP
    • MR/MRCP

Clinical Trial Outcome Measures

Primary Measures

  • cholangiocarcinoma
    • Time Frame: 10 yrs f-up
  • liver transplatation
    • Time Frame: 10 yrs f-up
  • death
    • Time Frame: 10 yrs f-up

Secondary Measures

  • biliary dysplasia
    • Time Frame: 10 yrs f-up

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of PSC by MR/MRCP
  • Life expectancy >1 year
  • Informed consent

Exclusion Criteria

  • Liver transplantation or on the waiting list
  • Secondry SC
  • Diagnosis of CCA

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Karolinska University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Annika Bergquist, professor – Karolinska University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.